The International Poetic and Cultural Manifestation “Ante Popovski – Ante’s quill” – a traditional event that is yet to become a synonym for the true values of the Macedonian literary reality

The text raises the question of the significance of literary manifestations for literary reality. The thesis is that the significance of a specific literary manifestation in this digital age is not predominantly conditioned by its format and how conventional or modern it is, but by whether its mission is primarily based on aesthetic and literary criteria and consequently, by its content – how much new impulses it gives to the literary life. As a confirmation of this perception, the text highlights the international poetic and cultural manifestation “Ante Popovski – Ante’s Quill”, which has been part of the Macedonian literary reality for four years. Although it is quite new, with an aspiration to become traditional manifestation, and although it is organized in a conventional format and program, without pretentious efforts for non-standard program contents, it is already recognizable on the Macedonian cultural map, as an event that simultaneously seeks to invest in the valorization and affirmation of the lasting values of the Macedonian culture, to promote the Macedonian literary production, to enable less affirmed authors to emerge from the shadows of living literary monuments and to encourage literary science. Moreover, the text analyzes and valorizes the achievements of this year’s edition of the manifestation. Particular emphasis is placed on the international scientific symposium which posed key and hitherto unactualized questions about the creative work of one of the greatest Macedonian authors of the 20th century – Ante Popovski. At the same time, the concept of the manifestation is analyzed, which is constantly evolving, enabling it to be an event that leaves a mark and can lead to happenings that will one day have to be written down in literary history.

Abstracts of the IV Scientific symposium with international participation “Musculoskeletal diseases and age” dedicated to the memory of V.V. Povoroznyuk (October 21–22, 2021, Kyiv, on-line)

No abstract

Abstracts from the 2nd Annual MI4 Scientific Symposium on December 4, 2020

N/A

On the 125th anniversary of S.A. Yesenin’s birth: from Paris to Konstantinovo

The review provides information about the main scientific and cultural events in honor of the 125th anniversary of the birth of Sergei Alexandrovich Yesenin (1895–1925), which took place in 2020. Among them is an evening in Paris as part of the XI Days of Russian Books and Russian-language Literature and Russian Seasons in France; the International scientific symposium “Sergei Yesenin in the XXI century”, held in Moscow, Ryazan and Konstantinovo; the exhibitions “‘Live as the star leads you...’: to the 125th anniversary of the poet’s birth” (State museum of the history of Russian literature named after V.I. Dahl); “I never lie with my heart” (House-museum of F.I. Chalyapin). The main scientific event of the anniversary year was the release of the first issue of the Yesenin Encyclopedia — “Memorable places. Literary geography”, prepared in IWL RAS.

Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020

The novel clinical data for plasma cell neoplasms (smoldering myeloma, multiple myeloma, and AL amyloidosis) that were presented in the 2020 American Society of Clinical Oncology virtual scientific symposium are summarized here. Data from large phase-3 studies (CASSIOPEIA, ENDURANCE, and TOURMALINE-MM4 trials) and phase-2 studies (SWOG 1211, GMMG CONCEPT trials) for newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation are described. Updates from previous important studies for multiple myeloma (STaMINA) along with studies on three different chimeric antigen receptor (CAR-) T cell products are also described. Results of clinical studies involving the use of anti-myeloma drugs with novel mechanisms of action such as immunoconjugates, selinexor, venetoclax, monoclonal antibodies, and data on minimal residual disease (MRD) are discussed. These data provide an overview of the efficacy and safety of the various treatments in multiple myeloma and could lead to changes in our clinical practice, which could pave the path for a “cure” in myeloma.